{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:51:27Z","timestamp":1772117487989,"version":"3.50.1"},"publisher-location":"Chichester, UK","reference-count":52,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd009882.pub2","type":"reference-entry","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T19:11:12Z","timestamp":1354821072000},"source":"Crossref","is-referenced-by-count":5,"title":["Teriflunomide for multiple sclerosis"],"prefix":"10.1002","author":[{"given":"Dian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"issue":"23","key":"10.1002\/14651858.CD009882.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318258f7d4","article-title":"Teriflunomide added to interferon-\u03b2 in relapsing multiple sclerosis: A randomized phase II trial","volume":"78","author":"Freedman","year":"2012","journal-title":"Neurology"},{"issue":"14","key":"10.1002\/14651858.CD009882.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009882.pub2-BIB3|cit3","first-page":"S182","article-title":"Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow-up","volume":"17","author":"Comi","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD009882.pub2-BIB4|cit4","first-page":"S409","article-title":"Long term safety and tolerability of teriflunomide in multiple sclerosis: 9-year follow-up of a phase II study","volume":"17","author":"Confavreux","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD009882.pub2-BIB5|cit5","unstructured":"Confavreux C Li D Freedman M Truffinet P Benzerdjeb H Wang D Long-term follow-up of a phase II study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years Multiple Sclerosis 1 12"},{"key":"10.1002\/14651858.CD009882.pub2-BIB6|cit6","first-page":"S183","article-title":"Efficacy of teriflunomide in relapsing multiple sclerosis: phase II extension study with 8-year follow-up","volume":"17","author":"Li","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD009882.pub2-BIB7|cit7","doi-asserted-by":"crossref","unstructured":"Miller AE O'Connor P Wolinsky JS Confavreux C Kappos L Olsson TP Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis Multiple Sclerosis 2012 1625 32","DOI":"10.1177\/1352458512450354"},{"issue":"6","key":"10.1002\/14651858.CD009882.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses","volume":"66","author":"O'Connor","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009882.pub2-BIB9|cit9","first-page":"S414","article-title":"Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization","volume":"17","author":"O'Connor","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD009882.pub2-BIB10|cit10","unstructured":"NCT00475865 Pilot Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis clinicaltrials.gov\/ct2\/show\/NCT00475865"},{"key":"10.1002\/14651858.CD009882.pub2-BIB11|cit11","unstructured":"NCT00751881 An\u00a0Efficacy\u00a0Study\u00a0of\u00a0Teriflunomide\u00a0in\u00a0Patients\u00a0With\u00a0Relapsing\u00a0Multiple\u00a0Sclerosis\u00a0(TOWER) clinicaltrials.gov\/ct2\/show\/study\/NCT00751881"},{"key":"10.1002\/14651858.CD009882.pub2-BIB12|cit12","unstructured":"NCT00803049 Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis clinicaltrials.gov\/ct2\/show\/study\/NCT00803049"},{"key":"10.1002\/14651858.CD009882.pub2-BIB13|cit13","unstructured":"NCT01252355 Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0Teriflunomide\u00a0in\u00a0Patients\u00a0With\u00a0Relapsing\u00a0Multiple\u00a0Sclerosis\u00a0and\u00a0Treated\u00a0With\u00a0Interferon-beta\u00a0(TERACLES) clinicaltrials.gov\/ct2\/show\/study\/NCT01252355"},{"issue":"2","key":"10.1002\/14651858.CD009882.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","article-title":"Temporal trends in the incidence of multiple sclerosis: a systematic review","volume":"71","author":"Alonso","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD009882.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrneurol.2009.41","article-title":"Imaging outcomes for neuroprotection and repair in multiple sclerosis trials","volume":"5","author":"Barkhof","year":"2009","journal-title":"Nature Review Neurology"},{"issue":"Pt 2","key":"10.1002\/14651858.CD009882.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/bj3360299","article-title":"Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide","volume":"336","author":"Bruneau","year":"1998","journal-title":"Biochemical Journal"},{"issue":"1","key":"10.1002\/14651858.CD009882.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.47.1.129","article-title":"Validation of the functional assessment of multiple sclerosis quality of life instrument","volume":"47","author":"Cella","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD009882.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-3565(25)24292-6","article-title":"The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism","volume":"272","author":"Cherwinski","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Pt 3","key":"10.1002\/14651858.CD009882.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"4","key":"10.1002\/14651858.CD009882.pub2-BIB20|cit20","first-page":"663","article-title":"Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases","volume":"9","author":"Deage","year":"1998","journal-title":"European Cytokine Network"},{"issue":"1","key":"10.1002\/14651858.CD009882.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis","volume":"18","author":"Devonshire","year":"2011","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD009882.pub2-BIB22|cit22","unstructured":"Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro (cladribine). 2011 European Medicines Agency http:\/\/bit.ly\/fvtzr1. [Accessed 30 August 2012]"},{"issue":"4","key":"10.1002\/14651858.CD009882.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135245859900500410","article-title":"Recent developments in the assessment of quality of life in multiple sclerosis (MS)","volume":"5","author":"Fischer","year":"1999","journal-title":"Multiple Sclerosis"},{"issue":"6","key":"10.1002\/14651858.CD009882.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0006-2952(95)00255-X","article-title":"Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide","volume":"50","author":"Greene","year":"1995","journal-title":"Biochemical Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD009882.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.bjp.0702708","article-title":"A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner","volume":"127","author":"Hamilton","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD009882.pub2-BIB26|cit26","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].The Cochrane Collaboration,2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009882.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1189\/jlb.0504308","article-title":"Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion","volume":"76","author":"Korn","year":"2004","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1002\/14651858.CD009882.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009882.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD009882.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.4049\/jimmunol.162.4.2095","article-title":"Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression","volume":"162","author":"Manna","year":"1999","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1002\/14651858.CD009882.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD009882.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00415-009-0075-3","article-title":"Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis","volume":"256","author":"Merrill","year":"2009","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD009882.pub2-BIB33|cit33","unstructured":"Merck Serono No Longer Seeking Approval for Oral Cladribine. 2011 Multiple Sclerosis Association of America www.msassociation.org\/news_center\/article.asp?a=_cladribine_not_seeking_approval. [Accessed 30 August 2012]"},{"issue":"5","key":"10.1002\/14651858.CD009882.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11532230-000000000-00000","article-title":"Economic burden of multiple sclerosis: a systematic review of the literature","volume":"28","author":"Naci","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD009882.pub2-BIB35|cit35","unstructured":"National MS Society Who gets MS? http:\/\/www.nationalmssociety.org\/about-multiple-sclerosis\/what-we-know-about-ms\/who-gets-ms\/index.aspx"},{"key":"10.1002\/14651858.CD009882.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PPA.S8230","article-title":"Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence","volume":"4","author":"Patti","year":"2010","journal-title":"Journal of Patient Preference and Adherence"},{"issue":"6","key":"10.1002\/14651858.CD009882.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD009882.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2010","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD009882.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD009882.pub2-BIB40|cit40","unstructured":"The Nordic Cochrane Centre, the Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"4","key":"10.1002\/14651858.CD009882.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.160.4.1581","article-title":"Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production","volume":"160","author":"Siemasko","year":"1998","journal-title":"Journal of Immunology"},{"issue":"4","key":"10.1002\/14651858.CD009882.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.0b013e3181ea15aa","article-title":"Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach","volume":"75","author":"Sormani","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD009882.pub2-BIB43|cit43","first-page":"62","article-title":"Spotlight on teriflunomide","volume":"15","author":"Tallantyre","year":"2008","journal-title":"International MS Journal"},{"issue":"4","key":"10.1002\/14651858.CD009882.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1191\/1352458504ms1059oa","article-title":"Clinical characteristics of progressive relapsing multiple sclerosis","volume":"10","author":"Tullman","year":"2004","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD009882.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1352458508096683","article-title":"The distribution of new enhancing lesion counts in multiple sclerosis: further explorations","volume":"15","author":"Elskamp","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD009882.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"issue":"1-2","key":"10.1002\/14651858.CD009882.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jns.2009.07.017","article-title":"Statistical methods for the analysis of relapse data in MS clinical trials","volume":"285","author":"Wang","year":"2009","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD009882.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36).I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD009882.pub2-BIB49|cit49","unstructured":"WHO Adherence to long-term therapies http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_report\/en\/index.html"},{"issue":"21","key":"10.1002\/14651858.CD009882.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"12398","DOI":"10.1074\/jbc.270.21.12398","article-title":"Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide","volume":"270","author":"Xu","year":"1995","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"10.1002\/14651858.CD009882.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(96)00303-6","article-title":"Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation","volume":"52","author":"Xu","year":"1996","journal-title":"Biochemical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD009882.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/art.21255","article-title":"Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation","volume":"52","author":"Zeyda","year":"2005","journal-title":"Arthritis and Rheumatism"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009882.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T00:00:00Z","timestamp":1458604800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009882.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:34:23Z","timestamp":1745393663000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009882.pub2"}},"subtitle":[],"editor":[{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009882.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969319.793471139","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2012,12,12]]}}}